ASHISH M KAMAT
Allopathic & Osteopathic Physicians|Urology HOUSTON, TX NPI 1114012895
Browse related groups: Allopathic & Osteopathic Physicians|Urology TX Janssen Research & Development, LLC All categories
General Payments — all program years on this page
$372,486.46
- Category: General Payments
- Program years: PY2018–2024
- Record count: 242
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $78,661.23 across 50 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $62,009.80 | 31 |
| Travel and Lodging | $10,151.70 | 7 |
| Honoraria | $4,000.00 | 1 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,755.00 | 1 |
| Food and Beverage | $744.73 | 10 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Research & Development, LLC | $35,656.25 | 11 |
| Merck Sharp & Dohme Corporation | $23,716.16 | 24 |
| Janssen Scientific Affairs, LLC | $4,725.00 | 1 |
| UROGEN PHARMA, INC. | $4,186.70 | 3 |
| Ferring Pharmaceuticals Inc. | $2,924.55 | 3 |
| E.R. Squibb & Sons, L.L.C. | $2,400.00 | 2 |
| PFIZER INC. | $1,969.03 | 2 |
| Acerta Pharma LLC | $1,257.29 | 2 |
| Astellas Pharma Global Development | $1,170.00 | 1 |
| Genentech, Inc. | $656.25 | 1 |
By program year
Records — PY2024 (50)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.